Glaxo challenges $2.7 billion transfer pricing claim
GlaxoSmithKline Holdings on April 2 2004 filed a petition in the US Tax Court contesting a multibillion-dollar transfer pricing claim. The US Internal Revenue Service (IRS) made its claim in January against Glaxo US, a US subsidiary of the UK-based pharmaceutical manufacturer GlaxoSmithKline.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: